Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
S&S Healthcare Holding Ltd. (4198.TWO)
Taipei, TW
S&S Healthcare Holding Ltd. is dedicated to the research, manufacturing, and global commercialization of medical imaging equipment. The company's operations extend across international markets, including significant presences in Taiwan, the United States, and Switzerland. Its product portfolio encompasses advanced digital diagnostic X-ray systems, alongside the engineering and production of devices for bone densitometry and body composition assessment. Established in 1988, S&S Healthcare maintains its headquarters in Taipei, Taiwan. The firm adopted its current name in August 2020, having previously operated as Swissray Global Healthcare Holding Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.35% | -0.53% | +1.35% | -6.25% | -3.60% | +2.74% | +2.88% | +50.60% | +14.16% | -91.09% | -96.85% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-15.0% Q1'26: -40.3% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-14.6% Q1'26: -14.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-13.6% Q1'26: -57.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-22.8% Q1'26: -28.7% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-25.5% Q1'26: -22.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.05× Q1'26: -1.38× (vs Q1'25)
| Metric |
Dec 2017 actual |
|---|---|
| Revenue |
494.85M
est.
|
| EBITDA |
-121.41M
est.
|
| EBIT |
-180.48M
est.
|
| Net Income |
—
est.
|
| SGA |
269.19M
est.
|
| EPS |
—
est.
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Tien-Ying Lee | Chief Operating Officer & Director | 18.0K | male |
| Yuxiang Huang | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4198.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
